Significance Of Neuron-specific Enolase Research Articles

PUB030 Use NSE and ProGRP to Judge Therapeutic

Small cell lung cancer (small cell lung cancer, SCLC) accounts for about 13% of lung cancer patients. Compared with non-small cell lung cancer. It has a early metastatic potential and sensitive to first-line cytotoxic chemotherapy. NSE and ProGRP in SCLC sometimes can be high. Collect 205 cases of untreated small cell lung cancer (SCLC) 2013-2016 in Peking Union Medical College Hospital, analysis their clinical data.Compare before and after the treatment course, peripheral blood tumor index of neuron specific enolase (NSE) and gastrin release peptide precursor (GRP) level and follow-up, through the comparison of the TTP, Cr rate data of NSE and ProGRP level on the treatment and prognosis of guiding significance. ORR, TTP, and 2 year survival rates were higher in abnormal NSE and ProGRP than in patients with normal NSE and ProGRP in patients with SCLC, but not statistically significant. NSE and ProGRP decreased to normal compared with the normal subjects after 4 chemotherapy, and had statistical significance. ORR, TTP, and 2 year survival rates of patients with normal SCLC and ProGRP were higher than those in patients with elevated NSE and ProGRP, and the elevation of and NSE showed poor prognosis. NSE and ProGRP decreased after chemotherapy, which indicated that the prognosis was good, especially the NSE decline was more significant. Therefore, ProGRP and NSE have a certain significance in predicting the prognosis and treatment effect of SCLC, and the significance of NSE is more prominent.

Prognostic significance of neuron-specific enolase in patients with diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy

The present study examined the clinical significance of serum neuron-specific enolase (NSE) in patients with diffuse large B-cell lymphoma (DLBCL). Serum NSE values were measured using a electrochemiluminescence assay in 106 patients and tissue NSE expression was examined using immunohistochemistry in 65 patients. Fifty-four percent of patients had a positive expression of serum NSE (>15.20 ng/mL), and cytoplasmic NSE was pathologically demonstrated in 26/65 cases, which showed a positive correlation with that of serum NSE expression. The serum NSE value was closely correlated with performance status, serum lactate dehydrogenase (LDH) level, International Prognostic Index (IPI) score, and Ann Arbor stage, and declined significantly in patients who responded to treatment. In the rituximab-immunochemotherapy group, there was a significant difference in the 5-year overall survival (OS) rate between the NSE-positive and -negative groups (93% vs. 44%, p = 0.001), and the serum NSE level was found to be an independent prognostic factor. Serum NSE may be a novel marker of disease aggressiveness as well as a prognostic factor for DLBCL in the era of rituximab.

The significance of NSE and CEA as a differentiation marker for the cellular heterogeneity of small cell lung cancer.

Neuron-specific enolase (NSE) and carcinoembryonic antigen (CEA) levels in the culture supernatant of the 65 pulmonary carcinoma cell lines: Small cell lung cancer (SCLC) 18, large cell carcinoma 14, squamous cell carcinoma 14, adenocarcinoma 14 and adenosquamous cell carcinoma 5, were measured by a radioimmunoassay (RIA). The mean value of NSE was 30.8+/-22.4 ng/ml and 9.2+/-8.7 ng/ml in SCLC and non-SCLC, respectively. The mean value of CEA was 15.1+/-20.9 ng/ml and 26.6+/-72.3 ng/ml in SCLC and non-SCLC, respectively. A significant difference in NSE levels was obtained between SCLC cell lines and non-SCLC cell lines. In SCLC cell lines, a significant inverse proportional correlation was observed between NSE and CEA levels. The CEA production tended to be higher in cells with low levels of NSE than in those with high NSE production. With respect to correlation between marker production and growth characteristics of SCLC cells in vitro, significantly higher NSE and lower CEA levels were found in cells growing with floating colony or neurite like characteristics (classic cell type) than those in cells with epithelial or intermediate growth characteristics (variant cell type). A significant positive correlation between NSE levels and the survival periods was found in follow-up studies of 10 patients who underwent surgery with complete resection of the primary tumor. All of 4 long term survivors over 3 years after surgery had significantly high NSE and relatively low CEA producing tumors. The relationship of these markers to clinical status of the patient suggests that an analysis for correlation of NSE and CEA levels in SCLC patients may be useful to discriminate between a pure neuroendocrine SCLC tumor and a mixed small cell/large cell tumor, and in monitoring therapeutic effect and prognosis of each patient.

Serum NSE, CEA, CT, CA 15-3 Levels in Human Lung Cancer

The significance of neuron specific enolase (NSE) was investigated in comparison with other tumor markers (CEA, CT, CA 15-3) used in the diagnosis and treatment monitoring of lung cancer. As previously described, the calcitonin assay proved to have very low sensitivity for small cell lung cancer (SCLC). The serum NSE assay was, however, shown to be a useful diagnostic aid for discrimination between histologically different lung cancers, and therefore this assay may be a valuable tool for treatment monitoring in SCLC patients. CA 15-3, also an unspecific marker, showed similar sensitivity to the NSE assay in SCLC patients, the sensitivity being higher than CEA in non small cell lung cancer (NSCLC).

Significance of neuron-specific enolase in diagnosis of bronchial carcinoma and neuroendocrine tumors

Significance of neuron-specific enolase in diagnosis of bronchial carcinoma and neuroendocrine tumors